Literature DB >> 29104288

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.

A Ray1, D S Das1, Y Song1, T Hideshima1, Y-T Tai1, D Chauhan1, K C Anderson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29104288      PMCID： PMC5842120          DOI： 10.1038/leu.2017.322

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Authors:  Dennis O Adeegbe; Yan Liu; Patrick H Lizotte; Yusuke Kamihara; Amir R Aref; Christina Almonte; Ruben Dries; Yuyang Li; Shengwu Liu; Xiaoen Wang; Tiquella Warner-Hatten; Jessica Castrillon; Guo-Cheng Yuan; Neermala Poudel-Neupane; Haikuo Zhang; Jennifer L Guerriero; Shiwei Han; Mark M Awad; David A Barbie; Jerome Ritz; Simon S Jones; Peter S Hammerman; James Bradner; Steven N Quayle; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-04-13       Impact factor: 39.397

3.  Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors:  A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

4.  Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authors:  Güllü Görgün; Mehmet K Samur; Kristen B Cowens; Steven Paula; Giada Bianchi; Julie E Anderson; Randie E White; Ahaana Singh; Hiroto Ohguchi; Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Teru Hideshima; Yu-Tzu Tai; Jacob P Laubach; Noopur Raje; Florence Magrangeas; Stephane Minvielle; Herve Avet-Loiseau; Nikhil C Munshi; David M Dorfman; Paul G Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 5.  Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.

Authors:  Karrune V Woan; Eva Sahakian; Eduardo M Sotomayor; Edward Seto; Alejandro Villagra
Journal:  Immunol Cell Biol       Date:  2011-11-22       Impact factor: 5.126

6.  Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

Authors:  Andrew J Yee; William I Bensinger; Jeffrey G Supko; Peter M Voorhees; Jesus G Berdeja; Paul G Richardson; Edward N Libby; Ellen E Wallace; Nicole E Birrer; Jill N Burke; David L Tamang; Min Yang; Simon S Jones; Catherine A Wheeler; Robert J Markelewicz; Noopur S Raje
Journal:  Lancet Oncol       Date:  2016-09-17       Impact factor: 41.316

7.  Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Authors:  Ashraf Badros; Elizabeth Hyjek; Ning Ma; Alexander Lesokhin; Ahmet Dogan; Aaron P Rapoport; Mehmet Kocoglu; Emily Lederer; Sunita Philip; Todd Milliron; Cameron Dell; Olga Goloubeva; Zeba Singh
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

8.  Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Authors:  Jennifer E Amengual; Paul Johannet; Maximilian Lombardo; Kelly Zullo; Daniela Hoehn; Govind Bhagat; Luigi Scotto; Xavier Jirau-Serrano; Dejan Radeski; Jennifer Heinen; Hongfeng Jiang; Serge Cremers; Yuan Zhang; Simon Jones; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2015-06-26       Impact factor: 12.531

9.  Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Authors:  Dharminder Chauhan; Ajita V Singh; Mohan Brahmandam; Ruben Carrasco; Madhavi Bandi; Teru Hideshima; Giada Bianchi; Klaus Podar; Yu-Tzu Tai; Constantine Mitsiades; Noopur Raje; David L Jaye; Shaji K Kumar; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.

Authors:  Jan M Klein; Alexander Henke; Maike Sauer; Martina Bessler; Katrin S Reiners; Andreas Engert; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240
View more
  20 in total

1.  Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Authors:  Arghya Ray; Yan Song; Ting Du; Dharminder Chauhan; Kenneth C Anderson
Journal:  Oncogene       Date:  2020-02-05       Impact factor: 9.867

2.  ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy.

Authors:  Seong-Jun Park; Sang Hoon Joo; Naeun Lee; Won-Jun Jang; Ji Hae Seo; Chul-Ho Jeong
Journal:  Arch Pharm Res       Date:  2021-11-10       Impact factor: 4.946

Review 3.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

4.  Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.

Authors:  Olasunkanmi O Olaoye; Paris R Watson; Nabanita Nawar; Mulu Geletu; Abootaleb Sedighi; Shazreh Bukhari; Yasir S Raouf; Pimyupa Manaswiyoungkul; Fettah Erdogan; Ayah Abdeldayem; Aaron D Cabral; Muhammad Murtaza Hassan; Krimo Toutah; Andrew E Shouksmith; Justyna M Gawel; Johan Israelian; Tudor B Radu; Niyati Kachhiyapatel; Elvin D de Araujo; David W Christianson; Patrick T Gunning
Journal:  J Med Chem       Date:  2021-02-12       Impact factor: 7.446

Review 5.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

Review 6.  Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Authors:  Preeti Kanikarla-Marie; Michael Lam; Alexey V Sorokin; Michael J Overman; Scott Kopetz; David G Menter
Journal:  Front Oncol       Date:  2018-04-20       Impact factor: 6.244

Review 7.  The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.

Authors:  Maria Cosenza; Samantha Pozzi
Journal:  Int J Mol Sci       Date:  2018-08-09       Impact factor: 5.923

Review 8.  Histone deacetylase 6 in cancer.

Authors:  Ting Li; Chao Zhang; Shafat Hassan; Xinyue Liu; Fengju Song; Kexin Chen; Wei Zhang; Jilong Yang
Journal:  J Hematol Oncol       Date:  2018-09-03       Impact factor: 17.388

Review 9.  Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.

Authors:  Rosemarie Tremblay-LeMay; Nasrin Rastgoo; Hong Chang
Journal:  J Hematol Oncol       Date:  2018-03-27       Impact factor: 17.388

Review 10.  Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Authors:  Yu-Tzu Tai; Shih-Feng Cho; Kenneth C Anderson
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.